Sanofi's Provention buyout hit with FTC delay. Will Pfizer's Seagen deal go off...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 11, 2023 at 12:02: PM
via The U.S. antitrust watchdog is taking more time to review the proposed combination of Sanofi and Provention Bio, two diabetes drug developers. Meanwhile, all eyes in biopharma are on the merger between Pfizer and Seagen.

article source
 




Top Bottom
Back
Quote